10 completed. 6 Phase 2, 3 Phase 1, 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow Timolol 0.5%: new trials by email Literature Review of Timolol 0.5% trials Research Report on Timolol 0.5%
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension H-1337 0.6%, H-1337 1.0%, H-1337 Placebo - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 2 | Completed | D. Western Therapeutics Institute, Inc. | 201 | 2023-08-28 | 2025-08-27 |
| Safety and IOP-Lowering Effects of WB007 WB007 0.05%, WB007 0.15%, WB007 0.4% - Glaucoma, Primary Open Angle, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Bausch & Lomb Incorporated | 77 | 2019-11-14 | 2025-03-27 |
| Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® PRO-122, Krytantek Ofteno® - Glaucoma | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 24 | 2019-05-02 | 2019-12-13 |
| A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension Fixed Combination, Bimatoprost, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | ForSight Vision5, Inc. | 55 | 2016-04-30 | 2019-02-25 |
| Dose-Ranging Study of the Bimatoprost Ocular Insert Bimatoprost, Timolol 0.5%, Placebo Ocular Insert - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 156 | 2015-01-19 | 2020-06-04 |
| Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension bimatoprost 0.01%, travoprost 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 100 | 2014-05-01 | 2016-01-14 |
| Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Bimatoprost, Timolol 0.5%, Placebo Eye Drops - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 169 | 2013-10-23 | 2018-04-20 |
| An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension bimatoprost 0.01%, travatan 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 93 | 2013-06-01 | 2015-11-30 |
| A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma Dorzolamide 2%, Timolol 0.5% - Glaucoma, Open-Angle | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 160 | 1999-05-01 | 2009-10-08 |
| A Study of Glaucoma or Ocular Hypertension in Patients Within the United States latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5% - Ocular Hypertension, Glaucoma | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 418 | 1997-07-01 | 2021-02-18 |
Ocular Hypertension (8) · Glaucoma, Open-Angle (6) · Glaucoma (5)
ForSight Vision5, Inc. (3) · Allergan (2) · Bausch & Lomb Incorporated (1) · D. Western Therapeutics Institute, Inc. (1) · Laboratorios Sophia S.A de C.V. (1) · Medical University of Vienna (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)
United States (6) · Austria (1) · Canada (1) · Mexico (1) · Panama (1)
Michelle Chen, PhD (3) · David Wirta, MD (1) · El-Roy Dixon, MD (1) · Hans G Eichler, MD, Prof. (1)